RxDoctor Payments DataLook up a doctor →

Jonathan Hamilton, MD

Urology · Greenville, NCNPI 1609965508

Payments from drug & device makers

$695,336in general payments, 2019–2025

Across 749 payments — averaging $928.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$270K
  • Astellas Pharma Global Development$201K
  • Dendreon Pharmaceuticals LLC$191K
  • Astellas Pharma US Inc$18K
  • Myriad Genetic Laboratories, Inc.$6K
  • Pfizer$2K
  • plus $6K from 32 others

What the payments were for

  • Consulting fees$3,6902%
  • Speaking & faculty fees$199,44489%
  • Travel & lodging$7,2163%
  • Food & beverage$13,2756%
  • Education$3060%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$695,336 in reported general payments places this provider in the 95th percentile of 434 urology providers in North Carolina.

See all urology providers in North Carolina

Medicare billing

Part B allowed, 2024
$279,128
Medicare patients
386
Services billed
10,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide110$1,262,016
NubeqaDarolutamide27$326,344
Thiola EcTiopronin12$93,509
GemtesaVibegron71$51,518
OrgovyxRelugolix20$48,899
MyrbetriqMirabegron46$28,125
Tamsulosin Hcl190$3,212
Methenamine Hippurate32$2,512
Solifenacin Succinate88$2,381
Silodosin17$1,365
Finasteride70$889
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst18$614
Oxybutynin Chloride15$481
Ciprofloxacin Hcl77$325
Venlafaxine Hcl ErVenlafaxine Hcl15$264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$18,345$1,290,140156 claims
BayerNubeqa$379$326,34427 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$103$100,41791 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 434 urology providers in North Carolina.

Other urology in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →